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Objectives. This study sought to determine whether the time to
first recurrence of syncope after a positive isoproterenol–tilt table
test result accurately predicts the eventual frequency of syncope.
Background. Both patient care and future clinical trials involv-
ing patients with neuromediated syncope will require a simple
measure that reflects the frequency of syncope. The time from tilt
table testing to the first recurrence of syncope might be such a
measure.
Methods. A cohort of 46 patients with syncope, in a university
outpatient clinic, who had at least one syncopal spell after a
positive isoproterenol–tilt table test result were followed up for up
to 6.5 years (mean [6SD] 48 6 14 months). The time from tilt
table testing to the first recurrence of syncope was correlated.
Results. A total of 40 of 46 patients had more than one
recurrent spell, with a median of eight recurrent spells. The time
to the first syncopal spell predicted the frequency of spells with
r 5 20.79 (p < 0.001), whereas the time to the second spell
predicted the frequency with r 5 20.92 (p < 0.001). Patients who
fainted within 1 month of tilt testing had a geometric mean
frequency of 1.35 spells/month (95% confidence limits 0.49, 3.74)
compared with patients who fainted 1 to 24 months after testing
(0.12 spells/month; 95% confidence limits 0.07 to 0.18, p < 0.001).
Finally, the frequency of syncopal spells bore no relation to the
duration of follow-up.
Conclusions. The time to the first recurrent spell predicts the
frequency of syncopal spells after a positive tilt table test result,
and the instantaneous risk of syncope is constant.
(J Am Coll Cardiol 1997;29:1284–9)
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Numerous studies with head-up tilt table testing have shown
that many patients with recurrent syncope have a syndrome of
neuromediated syncope. Interest is now turning to studies of
the outcome of this syndrome, partly to assist in patient
counseling and partly to help design clinical trials of therapeu-
tic interventions. Recently, we identified several clinical risk
factors that could be used to predict an early recurrence of a
syncopal spell after a positive tilt table test result (1). Factors
that predicted the time to first recurrence of syncope included
the number of historical syncopal spells, the duration of
syncopal symptoms, the frequency of syncopal spells and
several tilt test variables. Syncope was chosen as the primary
symptom because it was memorable and easily quantifiable and
because apprehension of syncope appears to be the main cause
of decreased quality of life in syncopal patients (2,3). The time
to first recurrence of syncope was chosen as the primary end
point because Pritchett and colleagues (4–6) had validated the
time to the first recurrence of arrhythmia as an accurate
measure of frequency of recurrences in atrial fibrillation and
supraventricular tachycardia.
However, the use of this multivariate predictive model has
potential drawbacks. It demands a reasonably accurate assess-
ment of the duration and frequency of historical syncopal
spells and is partly based on a specific tilt test protocol that
involved the use of high dose isoproterenol. Furthermore,
many patients have a marked decrease in their symptoms after
tilt testing (1,7). For these reasons we wished to develop a
simple, practical measure of the eventual frequency of syncope
after tilt table testing. In light of the proven usefulness of first
recurrence time in other paroxysmal disorders, it seemed
reasonable to attempt to validate the time to first recurrence of
syncope after tilt testing as an outcome measure in the
syndrome of neuromediated syncope.
This study had two purposes: 1) We wished to determine
whether the time to the first recurrence of syncope after a
positive tilt table test result predicts the frequency of syncope
during the long-term follow-up period; and 2) we wished to
determine whether the frequency of syncope was idiosyncratic
and constant for each patient, as would be expected for a
random process with idiosyncratic instantaneous relative risks.
Methods
Inclusion and exclusion criteria. Patients underwent tilt
table testing if they had had 1) two or more syncopal episodes;
or 2) one syncopal episode and four or more presyncopal
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episodes; or 3) a single episode of syncope causing serious injury
(1). Patients were eligible for this study if they were followed up
for at least 24 months after a positive isoproterenol–tilt table test
result and had at least one syncopal spell after the tilt test. The
24-month period was selected as a reasonably long period of
observation, and by definition patients had to have had at least
one recurrence of syncope to qualify for the study. Patients with
other causes of syncope were excluded from the study. In
particular, patients with structural heart disease, documented
ventricular tachycardia or bifascicular block also underwent am-
bulatory electrocardiography and programmed electrical stimula-
tion using a previously described protocol (8). In the global
patient cohort (n 5 338), which included patients with other
causes of syncope, 196 had a positive tilt table test result. Of these
196, 33 patients were lost to follow-up. The remaining 163
patients constitute the parent cohort of the subjects of this report.
The baseline clinical characteristics and tilt test variables of the
patients lost to follow-up closely resemble the characteristics of
the parent cohort (1).
Tilt table test. Patients underwent tilt table testing (9–11)
in a quiet room after they had fasted for 4 to 8 h. No patient
underwent tilt table testing while taking beta-adrenoceptor
blocking agents (9), disopyramide or drugs with anticholinergic
activity. They were comfortably restrained on an electric tilt
table. Instrumentation consisted of a peripheral intravenous
cannula and automatic and manual blood pressure cuffs. The
test ended after frank syncope during an infusion of 5 mg/min
of isoproterenol or after 10 min in the head-up position with
either presyncope or no symptoms. Heart rate, blood pressure
and symptoms were recorded each minute. Tilt test results
were deemed positive if they ended in syncope or presyncope
and a decrease in rate–pressure product to #9,000 mm Hg/min
(10).
Definitions. Duration of symptoms 5 number of months
elapsed between the first historical syncopal spell and the
diagnostic tilt table test; observation period 5 duration of
follow-up after the tilt table test; frequency of syncope 5
numerical ratio of the number of spells divided by the duration
of symptoms.
Interventions and follow-up. After tilt testing and a rest
period, all patients underwent counseling regarding the diag-
nosis, possible pathophysiology, lack of mortality and uncertain
symptomatic prognosis of neuromediated syncope. All patients
were reassured, counseled on recognizing their presyncopal
prodromal symptoms and urged to take specific appropriate
postural maneuvers when presyncopal. Throughout this study
we recognized the lack of Phase I to IV studies (12) demon-
strating drug efficacy. This was discussed, and no patient was
urged to accept empiric drug therapy. All patients who started
drug therapy did so at their own request. We used beta-
blockers (when not contraindicated) for initial treatment (9).
All patients were asked to notify the syncope clinic of their first
recurrence, and all were contacted at least every 6 months by
telephone.
Statistical analysis. The primary outcome measure was the
frequency of syncopal spells during follow-up, calculated as the
number of spells divided by the duration of the observation
period. Patients with large numbers of syncopal spells (usually
.10) were asked to estimate the frequency of syncopal spells
in demarcated epochs of follow-up. This frequency was then
converted to an estimate of the number of spells, which was
confirmed by the patient. Although this is accurate for patients
with few spells, some error can be expected with patients with
many spells. Dependent variables included the time from tilt
testing to the first recurrence, the time between the first and
second recurrences after tilt testing and the time from tilt
testing to the second recurrence.
We first determined whether the variable was normally
distributed or skewed. The skewed distributions were analyzed
after logarithmic transformation, and the data are presented as
geometric mean 6 95% confidence limits. Mean values (6SD)
and medians were calculated for continuous variables, and
frequencies were measured for categoric variables. Differences
between groups were examined for statistical significance by a
two-sample t test for continuous variables (using a logarithmic
transformation on skewed distributions where appropriate)
and by the Fisher exact test for categoric variables. Linear
regression was performed on appropriately transformed data.
Although the duration of observation was normally distributed,
the number and frequency of recurrent syncopal spells
were log distributed. Accordingly, the data analysis was per-
formed using in large part log-transformed data, which were
normally distributed with 80% confidence as assessed by the
Kolmogorov-Smirnov test. Because the primary hypothesis is
that the time to first spell is a reciprocal function of the
frequency of spells (as are heart periods the reciprocal of heart
rate), each relation takes the reciprocal form y 5 axb, where y
is the observed frequency, and x is the time to first syncope
recurrence. Because the constants a and b were derived from
log-normalized data, they are expressed as mean values and
95% confidence intervals.
Results
Study patients. A total of 46 patients had at least one
syncopal spell within the first 2 years after a positive tilt test
result (34 women, 12 men; mean age 32 6 17 years). They had
had a median of 17 spells (mean 223 6 916) over a median of
36 months (mean 68 6 79). They had a median frequency of
0.47 spells/month (mean 6 6 25) before tilt table testing.
During the tilt table test, 28 patients developed syncope, and
18 developed presyncope only.
Medication use during study period. No patient was taking
medication for prevention of syncope at the time of tilt table
testing. However, it was impossible to maintain most patients
in the drug-free state throughout the study. Most patients (n 5
35) at some point sought and received empiric attempts at
medical therapy. After the tilt test, 23 patients were started on
beta-blocking agent therapy, 3 received other drugs, and 20
were not treated. After the first syncopal recurrence, 28
patients received beta-blockers, 2 received other drugs, and 16
were not treated. After the first recurrence of syncope, 15
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patients had a change in the intention to treat (or not treat)
their syncope.
Recurrence characteristics. The patients were observed
for 44 6 18 months (range 24 to 80), which included the time
from the tilt test to the first syncopal spell. The total cohort had
a median of 8 recurrent syncopal spells (mean 241 6 969) with
a median posttest frequency of 0.28 spells/month (mean 6 6
22), and 40 of 46 patients had more than 1 recurrent spell.
Syncope recurred quickly after tilt testing (Fig. 1), with a
median time to first recurrence of 2.75 months (mean 5.3 6
6.9) and a median time between the first and second syncopal
spells of 2.0 months (4.4 6 5.6). The median time from the tilt
test to the second recurrence was 4.2 months (mean 8.8 6 9.7).
Eventual syncopal frequency and recurrence times. Figure
2 shows that log(Observed frequency) and log(Time to first
spell) correlate well (r 5 20.79, p , 0.001), according to the
relation Observed frequency 5 0.44(First recurrence
time)20.7. To determine whether the risk of syncope in each
patient changes over time, we assessed the relation between
the frequency of syncopal spells/patient as a function of the
length of follow-up. There was no correlation (r 5 20.03), in
keeping the concept that the risk of syncope for each patient
does not decline with time.
If each syncopal spell reflects a single observation in a
recurrent process, then increasing the number of observations
should allow a more precise estimate of the nature of the
process. To test this hypothesis, we correlated the time from
tilt test to the second recurrence of syncope with the final
observed frequency of syncope. Figure 3 shows that log(Ob-
served frequency) and log(Time to second spell) correlate well
(r 5 20.92, p , 0.001), according to the relation Observed
frequency 5 1.54 (First recurrence time)21.0. Similarly, the
interval between syncopal spells should be a function of the
reciprocal of the overall syncopal frequency. Figure 3 also
shows that log(Interval between first and second spells) and
log(Observed frequency) correlate well (r 5 20.85, p , 0.001),
according to the relation Observed frequency 5 0.65(Intersyn-
cope interval)20.91. In conclusion, syncope appeared to recur
with an idiosyncratic and constant frequency during the obser-
vation period.
Dichotomous values and eventual syncope burden. Al-
though smoothly continuous functions are helpful in predicting
the expected syncopal frequency in individual patients, they
are less helpful in designing clinical trials where entry criteria
require dichotomous values to guide patient enrollment. Ac-
cordingly, we calculated the average frequencies of syncope in
patients depending on whether they fainted within specified
times after tilt testing. These estimates are presented in Table
1. For example, patients with a first recurrence within 1 month
have a geometric mean syncope frequency of 1.35 spells/
month, whereas patients with a recurrence time .1 month
have a geometric mean syncope frequency of 0.12 spells/month
(p , 0.001).
Subgroup analyses. Four subgroup analyses were per-
formed to assess the robustness of the conclusions. First, we
compared the relations between the time to the first recurrence
of syncope in 11 patients who were never treated pharmaco-
logically for syncope with those relations in 35 patients who
were treated at some time during their clinical course after tilt
testing. The data in Figure 4 show the similarity between these
two groups; their relations are described in Table 2. Similarly,
we compared these relations in patients who were or were not
treated with beta-blockers at some time between tilt testing
and the first syncopal recurrence; in patients who were or were
not treated with beta-blockers after the first syncopal recur-
rence; and in patients whose intent to be treated was changed
or unchanged after the first syncopal recurrence. The data
(Table 2) show the great similarity in the constants in all
groups. All confidence intervals overlapped, suggesting that
Figure 1. Actuarial probabilities of remaining free of syncope after a
positive tilt test result in 46 patients who had at least one spell after a
positive tilt test (solid line), and in 40 patients who fainted after their
first recurrent spell (dashed line).
Figure 2. First recurrence times and eventual frequency of syncope.
The relation is Observed frequency 5 0.44(Time to first recur-
rence)20.77, with r 5 20.79, p , 0.001. The confidence limits of the
exponent are 20.58, 20.94.
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treatment had no effect on the relation between time to first
syncopal recurrence and eventual frequency of syncope.
Discussion
The present study demonstrates that the time to first
syncope recurrence is a simple, accurate method of predicting
the future frequency of syncope in patients with neuromedi-
ated syncope. The eventual frequency of syncope closely
correlates with a number of measures of the time between
syncopal spells, including the time between the first and second
recurrences, the time to first recurrence and the time to second
recurrence. The exponents are close to 21, the expected value
of a simple reciprocal relation. The best predictor of long-term
outcome is time to second spell (r 5 20.92). This increased
correlation coefficient may be due to the fact that this measure
samples two intervals—the time to first recurrence and the
time between first and second recurrences—and therefore is
more influenced by the true recurrence rate and less by the
sampling error of a single event.
We previously reported (1) a multivariate model of the
effect of risk factors on the time to the first recurrence of
syncope. The total number of historical syncopal spells, the
duration of symptoms and the frequency of spells were each
independent risk factors that predicted the time to first recur-
rence of syncope. This work validates the choice of time to first
syncope recurrence by demonstrating that it correlates well
with the eventual frequency of spells.
Choice of syncope as outcome measure. Outcome mea-
sures in studies of neuromediated syncope might include
syncope; combined recurrences of presyncope and syncope;
and quality of life (2,3). Syncope was chosen (1) because it is
easily quantifiable and memorable. Presyncope was not chosen
because of anticipated difficulties with its variable severity and
duration. Indeed, recurrent presyncope is likely to be a signif-
icant problem in the lives of these patients.
Figure 3. Top panel, Second recurrence times and eventual frequency
of syncope. The relation is Observed frequency 5 1.54(Time to second
spell)21. The confidence limits of the exponent are 20.85, 21.14.
Bottom panel, Interevent intervals and eventual frequency of syncope.
The relation is Observed frequency 5 0.65(Interval between first and
second spells)20.91. The confidence limits of the exponent are 20.72,
21.10.
Table 1. Relation of Observed Frequency of Syncopal Spells After
Tilt Test to Time to First Syncopal Spell After Tilt*
First Syncope No. of Pts
Observed Frequency of Syncopal
Spells/mo
Mean 6 SD
Geometric
Mean
(95% CL)
In #2 wk 14 18 6 38 2.2 (0.68, 7.17)
In .2 wk 32 0.27 6 0.32 0.14 (0.09, 0.22)
In #1 mo 19 13 6 33 1.35 (0.49, 3.74)
In .1 mo 27 0.20 6 0.21 0.12 (0.08, 0.18)
In #3 mo 27 9.5 6 28 0.84 (0.38, 1.86)
In 3–24 mo 19 0.13 6 0.14 0.09 (0.06, 0.13)
In #6 mo 32 8.3 6 26 0.69 (0.34, 1.42)
In .6 mo 14 0.09 6 0.07 0.07 (0.05, 0.11)
In #1 yr 40 6.4 6 23 0.43 (0.23, 0.81)
In .1 yr 6 0.06 6 0.04 0.05 (0.03, 0.09)
*Patients (Pts) were classified according to whether they fainted before or
after the specified dichotomous times of 2 weeks and 1, 3, 6 and 12 months. All
differences within pairs were significant at p , 0.001 for geometric means, and
p 5 0.047 to 0.053 for arithmetic means. CL 5 confidence limits.
Figure 4. First recurrence times and frequency of syncope in patients
who never received or ever received drug treatment after tilt testing.
1287JACC Vol. 29, No. 6 MALIK ET AL.
May 1997:1284–9 FREQUENCY OF SYNCOPE RECURRENCE
Probability of syncopal recurrence during follow-up. The
risk of syncope for each patient changes little during the
follow-up period. This contrasts with our previous report that
the probability of a first syncopal event in the cohort decreases
after a positive tilt test result (1). The most likely explanation
is that many patients learn early after assessment to abort the
progression of presyncope to syncope, thus reducing the
overall risk of syncope in the cohort. In contrast, patients who
cannot act on their presyncopal prodrome will go on fainting.
Patients with syncope occasionally appear to have clusters
of events over time. This study does not address this issue
because we examined only the average frequency of spells over
time. In this long duration of observation, these putative
clusters might not be detected. However, note that in the
relation Observed frequency 5 a(First recurrence time)b, the
constant a is ;0.44, indicating that the eventual frequency is
only half of the expected value based on the first recurrence
time. In this long duration of observation, putative clusters
might not be detected. To do so would require a prospective,
observational trial in which each event was recorded and no
changes were made in treatment.
Uses of first recurrence time. The first recurrence time can
be used to risk-stratify patients. Given that many patients may
have a reduced risk of syncope after assessment, some might
consider it reasonable to suggest that patients be followed up
without specific therapy and return for reassessment after the
first recurrence of syncope. Patients at low risk for frequent
recurrent spells would therefore be spared the potential ad-
verse effects and cost of treatment, and patients at high risk
would gain a better estimate of their future course. Similarly,
patients who do not have a recurrence within a specific
follow-up period might be allowed to resume driving, whereas
those with early recurrences might be specifically counseled to
refrain from driving (13). The first recurrence time can also be
used as a study outcome measure, as is done in studies of
paroxysmal arrhythmias (14,15). It is simple, validated and
does not require that patients continue receiving possibly
ineffective therapy for long periods while having recurrent
syncopal spells.
Finally, the first recurrence time can be used to provide
estimates of event probabilities that are necessary for sample
size calculations. The data in Table 1 provide for the enroll-
ment of high risk patients in trials where the outcome measure
is the number of syncopal spells within a defined time, and the
relations in Figure 3 provide for the enrollment of patients in
trials where the outcome measure is the time to first syncopal
recurrence.
Study limitations. This study has several limitations. We
did not conduct pure natural history study of patients in a
drug-free state. Ideally, we would have studied the natural
history of patients who received no attempts at specific therapy
for syncope. Because recurrent syncopal and presyncopal
spells pose significant morbidity, many patients sought and
received pharmacologic attempts at therapy. It is possible that
the medications altered the eventual temporal behavior of our
study cohort. However, the high correlation coefficients and
the results of the subgroup analyses suggest the robustness of
the relations between interevent intervals and recurrence
frequencies.
This report concerns patients with a positive outcome in
response to the isoproterenol–head-up tilt table test protocol
used in our laboratory. Therefore, we cannot comment on the
long-term outcome of patients with a positive outcome in
response to passive prolonged head-up tilt testing (16,17) or to
tilt testing using one of a variety of other provocative agents,
such as nitroglycerin (18), or a different dose of isoproterenol
(19–21). These limitations are particularly relevant because
the sensitivity and specificity of the various protocols may differ
(22,23).
We used syncope, not presyncope, as the outcome measure.
However, part of our clinical interaction with patients included
teaching the specific physical maneuvers to abort the progres-
sion of presyncope to syncope. If successful, this might reduce
the risk of syncope without reducing the clinical burden of
presyncope.
This study focused on a highly symptomatic, young cohort;
half the patients had had .17 historical syncopal spells, and
the mean age was 32 years. This was not our explicit intention
Table 2. Relation Between Time to First Recurrence of Syncope and Observed Frequency of Syncopal
Spells in Selected Subgroups*
No. of Pts r Coeff Slope Exponent
Ever treated 35 20.77 0.46 (0.29, 0.75) 20.76 (20.98, 20.53)
Never treated 11 20.86 0.37 (0.18, 0.73) 20.75 (21.1, 20.41)
Beta-blockers after tilt test 23 20.71 0.38 (0.20, 0.73) 20.67 (20.96, 20.37)
Drug free after tilt test 20 20.84 0.44 (0.26, 0.75) 20.82 (21.1, 20.55)
Beta-blockers after 1st faint 28 20.76 0.41 (0.26, 0.66) 20.67 (20.90, 20.44)
Drug free after 1st faint 16 20.78 0.38 (0.18, 0.79) 20.74 (21.1, 20.41)
Change in intention to treat 15 20.82 0.48 (0.21, 0.91) 20.75 (21.21, 0.29)
No change in intention to treat 31 20.70 0.42 (0.27, 0.66) 20.76 (20.96, 20.56)
Total cohort 46 20.79 0.44 (0.33, 0.64) 20.76 (20.94, 20.58)
*Subgroups are described in the Results section. Slope and exponent refer to the constants a and b, respectively, in
the relation Syncopal frequency 5 a(Time to recurrence)b. The value for a simple reciprocal relation is 21. Because the
constants a and b were derived from log-normalized data, their values are expressed as mean value (95% confidence
limits). Change in intention to treat refers to clinical decisions after the first recurrent faint. Coeff 5 coefficient.
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because the inclusion criteria specified that patients need only
have a positive tilt test result and at least one syncopal spell
within a follow-up period lasting at least 2 years after tilt
testing. The study cohort otherwise was broadly representative.
The patients had a broad age range and presented with a wide
range of historical number of syncopal spells and duration of
symptoms.
We did not assess the use of a pretest interevent interval as
a predictor of eventual frequency in patients who did not
undergo tilt table testing. The impact of the tilt test itself on
long-term outcome is unknown, and untested patients include
those who will have a negative tilt table test. Whether these
patients behave similarly is unknown, although we have pre-
sented preliminary data indicating that this may be so (24).
Hence, our results may not apply to patients without a tilt test.
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